Kind Pharmaceutical key facts
- Develoepr of drugs and treatments designed for kidney disease and cancer.
- It has raised $141.2M; the latest was Later Stage VC ($56.2M) in Nov 2025.
- Notable investors include Northern Light Venture Capital, Shenzhen Yifeng Investment Management Enterprise, Xiamen C&D Corporation, GDD Industry Fund, Taikun Fund — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Kind Pharmaceutical
13+Membership and data by Private Market View
- ·The complete investor list: 13 names
- ·Watch Kind Pharmaceutical: the Monday email on marks, rounds and moves
Kind Pharmaceutical funding rounds
No funding rounds for Kind Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kind Pharmaceutical investors
13 investors are on record for Kind Pharmaceutical, including Northern Light Venture Capital, Shenzhen Yifeng Investment Management Enterprise, Xiamen C&D Corporation and GDD Industry Fund.
About Kind Pharmaceutical
Develoepr of drugs and treatments designed for kidney disease and cancer. The company's main research project is the self-developed oral small-molecule compound, which is primarily used to treat anemia associated with chronic kidney disease. providing patients with effective treatment for the kidneys.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Website
- kindpharmaceutical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kind Pharmaceutical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.